TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 18, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Mary Szela Chief Executive Of ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 18, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) 85-3009869 (I ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 Delaware (State or other jurisdiction of incorporation or organization) Westminster, Colorado 80031 (888) 321-5212 (Address, including zip co ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 Delaware (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 6272 W. 91st ...

TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 31, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 8071 (Primary Standard Industrial 85-3009869 (I.R.S. Employer Identification No.) Delaware (State or other jurisdiction of incorporation or organization) 6272 W. 91st Ave. W ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 31, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 8071 (Primary Standard Industrial 85-3009869 (I.R.S. Employer Identification No.) Delaware (State or other jurisdiction of incorporation or organization) 6272 W. 91st Ave. W ...

Financial Performance - The company reported a net loss of $995,039 for the three months ended June 30, 2023, with general and administrative expenses of $1,429,989[157]. - For the six months ended June 30, 2023, the company had a net loss of $1,443,136, with general and administrative expenses totaling $2,273,335[158]. - Cash used in operating activities for the six months ended June 30, 2023 was $1,012,320[163]. - The company incurred $30,000 in fees for administrative services for the three months ended June 30, 2023, consistent with the previous year[176]. Initial Public Offering - The company generated gross proceeds of $250,000,000 from its Initial Public Offering of 25,000,000 units at $10.00 per unit[161]. - The company incurred $14,161,525 in Initial Public Offering related costs, including $5,000,000 of underwriting fees[162]. - The underwriters of the Initial Public Offering are entitled to a deferred fee of $8,750,000, payable only upon the completion of an initial business combination[178]. Business Combination - The company plans to consummate the TriSalus Business Combination during the third quarter of 2023[167]. - The TriSalus Business Combination is subject to certain closing conditions and involves the merger of MTAC Merger Sub with TriSalus Life Sciences, Inc.[152]. - The company intends to use substantially all funds held in the trust account to complete its business combination[166]. - The company has until September 22, 2023, to consummate an initial business combination, or it will face mandatory liquidation[174]. Trust Account and Investments - As of June 30, 2023, the company had investments held in the trust account amounting to $12,076,340[165]. Promissory Notes - As of June 30, 2023, the outstanding balance under the 2021 Promissory Note is $544,000, which is non-interest bearing and matures upon the closing of the initial business combination[168]. - The 2022 Promissory Note I has an outstanding balance of $400,000 as of June 30, 2023, also non-interest bearing and maturing upon the closing of the initial business combination[169]. - The outstanding balance under the 2022 Promissory Note III is $629,222 as of June 30, 2023, with no amount outstanding as of December 31, 2022[170]. - The 2022 Convertible Promissory Note has an outstanding balance of $1,500,000 as of June 30, 2023, which may be converted into warrants at a price of $1.50 per warrant[171]. - The First Extension Note has an outstanding balance of $234,411 as of June 30, 2023, up from $39,068 as of December 31, 2022[172]. - The Second Extension Note has an outstanding balance of $22,896 as of June 30, 2023, related to the extension of the termination date[173]. Liabilities - As of June 30, 2023, there are no off-balance sheet financing arrangements or long-term liabilities other than a monthly fee of $10,000 to the Sponsor for administrative support[175][176].

Financial Performance - For the three months ended March 31, 2023, the company reported a net loss of $448,097, consisting of general and administrative expenses of $843,346, offset by a change in fair value of warrant liabilities of $265,334 and interest earned on marketable securities of $157,033 [154]. - The company reported a net income of $2,836,725 for the three months ended March 31, 2022, primarily due to a change in fair value of warrant liabilities of $3,449,332 [155]. Initial Public Offering (IPO) - The company generated gross proceeds of $250,000,000 from its Initial Public Offering of 25,000,000 units at $10.00 per unit [156]. - The company incurred $14,161,525 in Initial Public Offering related costs, including $5,000,000 in underwriting fees and $8,750,000 in deferred underwriting fees [157]. - The total deferred fee to underwriters from the Initial Public Offering amounts to $8,750,000, contingent upon the completion of an initial business combination [174]. Business Combination - The company entered into a Business Combination Agreement with TriSalus Life Sciences, Inc., with the merger subject to certain closing conditions [149]. - The company has until June 22, 2023, to consummate an initial business combination, after which a mandatory liquidation will occur if not completed [169]. Cash and Investments - As of March 31, 2023, the company had investments held in the trust account amounting to $20,219,328, with no withdrawals made from the interest income during the period [160]. - As of March 31, 2023, the company had cash of $136,798, intended for business due diligence and completion of the initial business combination [162]. - Cash used in operating activities for the three months ended March 31, 2023, was $698,415, with changes in operating assets and liabilities providing $172,049 of cash [158]. Liabilities and Obligations - The company issued a promissory note to the Sponsor for $544,000, which is non-interest bearing and matures upon the closing of the initial business combination [163]. - As of March 31, 2023, the company has no off-balance sheet financing arrangements or obligations, ensuring a clean balance sheet [170]. - Legal fees of $508,525 and investment advisory fees of $400,000 were incurred but are no longer due following the termination of the Memic Business Combination Agreement [176]. Accounting and Financial Instruments - The company evaluates its financial instruments, including warrants, and classifies them as liabilities at fair value, subject to re-measurement at each reporting period [180]. - Class A common stock subject to possible redemption is classified as temporary equity, reflecting certain redemption rights outside the company's control [181]. - The company has not adopted the new accounting standard ASU 2020-06 as of March 31, 2023, which is effective January 1, 2024 [183]. Risks and Challenges - Various factors, including economic downturns and geopolitical instability, may adversely affect the company's results of operations and ability to complete an initial business combination [185].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39813 MedTech Acquisition Corporation (Exact name of registrant as specified in its charter) Delaware 85-3009869 (Sta ...

Financial Performance - The company had a net income of $659,457 for the three months ended September 30, 2022, driven by interest income of $1,017,632 from marketable securities [140]. - For the nine months ended September 30, 2022, the company reported a net income of $5,882,421, which included a change in fair value of warrant liabilities of $6,102,666 [141]. - Cash used in operating activities for the nine months ended September 30, 2022, was $1,471,286, with net income impacted by a change in fair value of warrant liabilities [148]. - Net income per common stock is calculated by dividing net income by the weighted average number of common stock outstanding, with two classes of common stock sharing income and losses pro rata [167]. Investments and Assets - As of September 30, 2022, the company held investments in the Trust Account amounting to $251,018,841, with $378,000 withdrawn during the nine months for tax payments [150]. - The company generated gross proceeds of $250,000,000 from its Initial Public Offering of 25,000,000 Units at $10.00 per Unit [144]. - The company has no long-term debt or off-balance sheet financing arrangements as of September 30, 2022 [158]. Initial Public Offering (IPO) Costs - The company incurred $14,161,525 in Initial Public Offering related costs, including $5,000,000 in underwriting fees [147]. - The underwriters are entitled to a deferred fee of $8,750,000, contingent upon the completion of an initial business combination [160]. Accounting and Financial Instruments - The Company evaluates its financial instruments, including stock purchase warrants, to determine if they qualify as derivatives, classifying them as liabilities at fair value [163]. - Class A common stock subject to possible redemption is classified as temporary equity and measured at fair value, reflecting uncertain future events [164]. - The Company is assessing the impact of ASU 2020-06, effective January 1, 2024, which simplifies accounting for certain financial instruments and introduces additional disclosures [168]. - Management does not believe that recently issued accounting standards will materially affect the condensed financial statements [169]. - The Company has not adopted the new accounting guidance as of September 30, 2022 [168]. Risks and Concerns - The company has until December 22, 2022, to consummate an initial business combination, raising concerns about its ability to continue as a going concern [156]. - Various factors, including economic downturns, inflation, and geopolitical instability, may adversely affect the Company's results of operations and ability to complete an initial business combination [170]. - The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks [163]. Valuation of Warrants - The Private Placement Warrants were valued using a Monte Carlo Simulation Model, while Public Warrants were valued based on quoted market prices after detachment from Units [163]. - Shares of Class A common stock with redemption rights are presented as temporary equity, outside of the stockholders' deficit section of the balance sheets [166]. Administrative Costs - The company incurred $30,000 in fees for administrative services for the three months ended September 30, 2022 [159].